To assess the functional significance of the changes induced by rs822336 on the clinical activity of anti-PD-1 based immunotherapy and/or PD-L1 induction by IFN-ɣ, we investigated the effect of anti-PD-1 mAb nivolumab on the recognition of NSCLC cells carrying different rs822336 genotypes by activated HLA class I antigen matched peripheral blood mononuclear cells (HLA-matched PBMCs). The gene discussed is IFNA1; the disease is non-small cell lung carcinoma.